Pro Medicus co-founders just sold off 2 million shares. Should you follow?

Pro Medicus is in the spotlight following the $513 million share sale by its co-founders.

| More on:
Health professional working on his laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Pro Medicus Ltd (ASX: PME) shares are in the green today.

Again.

Shares in the S&P/ASX 200 Index (ASX: XJO) health imaging company closed yesterday at $256.73. In early morning trade on Wednesday, they are changing hands for $259.01 apiece, up 0.9%.

For some context, the ASX 200 is down 0.3% at this same time.

Created with Highcharts 11.4.3Pro Medicus PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

As you can see on the chart above, Pro Medicus shares have been shooting the lights out of late, up 192% over the past year. And if that's not enough, the stock also trades on a slender 0.2% fully franked trailing dividend yield.

Which brings us to the sale of two million shares by the company's co-founders.

Two million Pro Medicus shares for $513.5 million

This morning, the health imaging company confirmed media speculations that its co-founders, Sam Hupert and Anthony Hall, both sold one million Pro Medicus shares at yesterday's closing price of $256.73 a share.

In other words, they've each just pocketed a cool $256.7 million.

Hall and Hupert launched the company in 1983. Pro Medicus listed on the ASX 17 years later, in October 2000.

While the stock has broadly trended higher since then, it didn't lift off right away. In August 2001, you could have bought shares for just 90 cents each.

If only!

The board noted that the co-founders' share sale "was in response to strong approaches from a number of high-quality funds", and that the shares were not sold at a discount to market prices.

The board also highlighted that the two million shares represented less than 4% of both Hall's and Hupert's stockholdings in the company. The co-founders remain the two largest shareholders, owning more than 24 million shares each.

There are a total of 104.5 million Pro Medicus shares outstanding.

According to the board, Hupert and Hall "are actively engaged in the company as executives and board members and are committed to its future. They remain the two key stake holders in the company with their combined holding post this recent sale of 46%."

Both co-founders said they had no plans to sell any additional Pro Medicus shares in the foreseeable future.

Commenting on the sale, Pro Medicus chairman Peter Kempen said:

This sale of shares by the founders is part of a progressive sell down, which provides prospective shareholders with the opportunity to invest in the company and ultimately will increase the free float.

Should you follow suit?

Every investor needs to decide what's right or their own personal situation.

Broadly speaking, Pro Medicus shares have been storming higher on the back of strong, ongoing growth.

At its full-year FY 2024 results, the company reported a 29.3% year on year increase in revenue to $161.5 million. Net profit soared 36.5% to $82.8 million.

Hupert also sounded a positive note on the company's outlook at the time, saying, "We have a bit over 7% of the total addressable market (TAM) in the US and growing, so there is still a huge amount of runway ahead of us."

Indeed, Bell Potter believes Pro Medicus shares can still move higher from here (courtesy of The Australian).

The broker just upped its price target for Pro Medicus shares by 100% to $260.00.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »